

REFERENCES

References

- ADAM (2002):** Agents Used for Cutaneous and Mild Lupus Erythematosus, ©2002 A.D.A.M., Inc. (or its subsidiaries).
- Agarwal S, Tafel AA, and Kanaar R (2006):** DNA double-strand break repair and chromosome translocations. *DNA Repair*; 5 (9-10): 1075-81.
- Aghazadeh-Habashi A, and Jamali (2003):** Pharmacokinetic study of meloxicam in the rat; *J Pharm Pharmaceut Sci*; Canadian Society for Pharmaceutical Sciences, CSPS 6th Annual Symposium, The science of Drug Discovery and Development; P 53, 54.
- Aljanabi SM, and Martinez I (1997):** Universal and rapid salt-extraction of high quality genomic DNA for PCR-based techniques. *Nucleic acids research*; 25: 4692-93.
- Andrikoula, M. and Tsatsoulis, A. (2001):** The role of Fas-mediated apoptosis in thyroid disease. *Eur. J. Endocrinol.*; 144:561-8.
- Anilkumar, T.V.; Sarraf, C.E. and Alison, M.R. (1992):** The biology and pathology of programmed cell death (apoptosis). *Vet. Hum. Toxicol.*; 34(3):251-4.
- Anning PB, Coles B, Morton J and et al,(2006):** Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. *Blood*; 108(13): 4059–62.
- Anon (2004):** 575-6996 bioassay @ wt.net<mailto: bioassay @wt.net>
- Ashkenazi A. and Dixit V.M. (1998):** Death receptors: signaling and modulation. *Science*; 281: Pp 1305-8.
- Baek S, Wilson L, Lee C, and et al (2002):** Dual Function of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Inhibition of Cyclooxygenase and Induction of NSAID-Activated Gene; *The Journal of Pharmacology and Experimental Therapeutics*; 301(Issue 3): 1126-31.

References

- Banks AT, Zimmerman HJ, Ishak KG and et al (1995):** Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions. *Hepatology*; 22(3):820-7.
- Barakat NS (2006):** Etodolac-Liquid-Filled Dispersion into Hard Gelatin Capsules: An approach to improve dissolution and stability of etodolac formulation; *Drug Development and Industrial Pharmacy*, Taylor & Francis; 32(7): 865 -76.
- Baumgartner A, Schmid TE, Cemeli E and et al (2004):** Parallel evaluation of doxorubicin-induced genetic damage in human lymphocytes and sperm using the comet assay and spectral karyotyping. *Mutagenesis*; 19 (4): 313-18.
- Baybek S, Erkeköl F O, Dursun B, and et al (2006):** Meloxicam-associated anaphylactic reaction. *J Investig Allergol Clin Immunol*; 16(5): 317-20. www.unboundmedicine.com/medline/ebm/mesh/Thiazines?start=0&next=true
- Berde C, and Sundel R (1998):** COX-2 Inhibitors: A Status Report. International Association for the Study of Pain®; Technical Corner from IASP Newsletter, September/October 1998
- Bingham CO (2002):** Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis; *Cleveland Clinical Journal of Medicine*; 69(1): 5-12.
- Boldin MP, Goncharov TM, Goltsev YV, and et al (1996):** Involvement of MACH, a novel MORT1/FADD- interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. *Cell*; 85:803-15.
- Boldin MP, Vartolomeev EE, Pancer Z, and et al (1995):** A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. *J Biol Chem*; 270:7795-8.

References

- Boothe DM (1999):** Non-steroidal anti-inflammatories and cyclooxygenase: is there a basis for selection? Texas A&M University, College Station, TX, Introduction: NSAID Mechanism of Action; file://NSAIDS- cox.htm.
- Brøgger A, (1982):** SCE and Chromosomal Mutation I, The chromatid gap - a useful parameter in genotoxicology? Cytogenet Cell Genet; 33(1-2):14-9.
- Bronstein AC (2004):** Nonsteroidal anti-inflammatory drugs. In: Medical Toxicology. Dart RC, Caravati EM, McGuigan MA, and et al (Eds); Lippincott Williams & Wilkins (3rd ed): pp.750-55.
- Brooks W C (2006):** The pet pharmacy. Permanent Link: <http://www.VeterinaryPartner.com/Content.plx?P=A&A=1752>
- Brown K E (2007):** Top ten drug interactions most dangerous to seniors in long-term care. E-mail - editor@SeniorJournal.com
- Bulten J, Melchers WJ, Kooy-Smits M.M, and et al (2002):** Numerical aberrations of chromosome 1 in cervical intraepithelial neoplasia are strongly associated with infection with high-risk human papillomavirus types. The Journal of Pathology; 198(3): 300-9.
- Burch W, Dusterberg B, and Schulte-Hermmn R (1986):** Growth, regression, and cell death in rat liver as related to tissue levels of the hepatomitogen cyproterone acetate. Arch Toxicol; 59:221-7.
- Carrano AV, Thompson LH, Lindl PA, and et al (1978):** Sister chromatid exchanges as an indicator of mutagenesis. Nature; 271: 551-3.
- Carson DA, Cottam HB, Souchi A, and et al (2006):** Use of etodolac for the treatment of prostate cancer. <http://www.freepatentsonline.com/7105561.html>

References

- Caulkett N, Read M, Fowler D, and et al (2003):** A comparison of the analgesic effects of butorphanol with those of meloxicam after elective ovariohysterectomy in dogs. *Can Vet J*; 44(7) 565--70.
- Chandragiri SS, Pasol E, and GallagherRM (1998):** Lithium, ACE Inhibitors, NSAIDs, and Verapamil A Possible Fatal Combination. Case Report; *Psychosomatics* 39:281-2.
- Chandrasekharan NV, and Simmons DL, (2004):** The cyclooxygenase. *Genome Biology*; 5(9):241; <http://genomebiology.com/2004/5/9/241>
- Chinnaiyan AM, ORourke K, Tewari M, and et al (1995):** FADD, a novel death domain-containing protein, interact with the death domain of Fas and initiates apoptosis. *Cell*; 81:505-12.
- Clive DM, and Stoff JS (1984):** Renal syndromes associated with nonsteroidal anti-inflammatory drugs; *The New England Journal of Medicine*; 310(9):563-72.
- Cole CA (2006):** NSAIDs in Equine Practice: Best Practices. IDEXX Pharmaceutical, Inc. Greensboro, North Carolina. Originally titled New Analgesic and New Thoughts on Old Analgesics in the Horse; presented at the North American Veterinary conference, January 2006.
- Connor JM, and Ferguson-Smith MA (1984):** Physical basis of heredity, chromosomes and chromosome aberrations. In: *Essential Medical Genetics*, 1st Edn., Blackwell Scientific Publications, Oxford, London, Edinburgh, Boston, Palo Alto, Melbourne. pp: 435-438. Cited from; pattern and evaluation of alcohols toxicity in patients referred to forensic medicine, poisoning and addiction control center with special emphasis on toxicity in albino rats; Thesis by Hegazy MM, Ass. Lecturer, forensic

References

- medicine, and clinical toxicology; Badawy SM, Kamel SM, Mahmoud BL, et al (supervisors); 2005 p 77.
- Copeland RL (2008):** Analgesic-antipyretic & anti-inflammatory agents ,Microsoft PowerPoint Presentation
- Cormack DH (1987):** Ham's Histology, 9th Edn., Lippincott Company, Philadelphia, London, Mexico City, New York. pp: 985-987.
- Cronstein BN (2002):** Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility. Cleve Clin J Med; 69:S113-S19.
- Cuschieri A, and Backer PR (eds) (1977):** Introduction to research. In: Medical Sciences. Churchill Livingstone Edinburg, London, P 16.
- Cybulsky AV (2007):** Cyclooxygenases, Prostanoids, and Glomerular Injury: Complex Relationships. J Am Soc Nephrol 18: 367-368, 2007.
- Dannhardt G, and Kiefer W (2001):** Cyclooxygenase inhibitors—current status and future prospects. Eur J Med Chem; (36):109-26.
- Dajani EZ, Shahwan TG, and Dajani NE (2003):** Prostaglandins and brain-gut axis. Journal of Physiology and Pharmacology; 54, (4): 155-64.
- Daniel WW (1991):** Biostatistics: A foundation for analysis in the health science. 5th ed., John Wiley and Sons. PP: 160-6.
- Davis WM, and Vinson MC (2001):** Cover story; New drug approvals of 2000-part 1. www.drugtopics.com; 51-5.
- Derle DV, Gujar KN, and Sagar BSH (2006):** Adverse effects associated with the use of nonsteroidal antiinflammatory drugs: An overview. Indian Journal of Pharmaceutical Sciences; 68 (4): 409-14.
- DeRuiter J (2002):** Nonsteroidal antiinflammatory drugs (NSAIDs); Principles of drug action 2, Fall: 1-25.
- Desai NS(2006):** Toxicity, Nonsteroidal Anti-inflammatory Agents.Toxicology. topic341.htm

References

- Distel M, Mueller C, Bluhmki E, and Fries J (1996):** Safety of meloxicam: a global analysis of clinical trials. *Brit J Rheumatol*; 35(1):68-7.
- Drug Bank (2006):** Meloxicam; Microsoft Internet Explorer-[Working Offline].
- Earnshaw WC, Martins LM, Kaufmann SH, and et al (1999):** Structure, activation, substrates, and functions during apoptosis. *Annu Rev Biochem*; 68: 383-24.
- Eis MJ, Watkins BM, Philip A, and et al (1998):** Nonsteroidal-induced benign strictures of the colon: A case report and review of the literature. *Am J Gastroenterol*; 93:120-1.
- Elder DJ, Halton DE, Playle LC, and et al (2002):** The MEK/ERK pathway mediates COX-2-selective NSAIDs-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. *Int J Cancer*; 99(3): 323-7.
- Ellenhorn MJ, Schonwald S, Ordog G, and et al {Eds} (1997):** Non steroidal anti-inflammatory drugs. In: *Ellenhorn's Medical Toxicology: Diagnosis and Treatment of Human Poisoning*. 2nd ed., Ch.11. Williams & Wilkins A Waverly Company, London. PP 196-6.
- EMA (1999):** The European Agency for the Evaluation of Medical Products; Committee for veterinary Medicinal products Meloxicam; summary report (i). E-Mail: mail @emea.eudra.org
<http://www.eudra.org/emea.html> P 1-7.
- Emery, A.E. (1983):** Elements of Medical Genetics, 6th Edn. Churchill Livingstone, London, New York.pp: 354-57.
- Feldman M and McMahon AT (2000):** Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? *Annals of Internal Medicine*; 132(2): 134 -3.

References

- Fitz-Gerald GA, and Patrono C (2001):** The Coxibs, Selective Inhibitors of Cyclooxygenase-2. *NEJM*; 345(6):433-42.
- Flemming, W. (1992):** Beitrage zur kenntniss der zelle and ihre Lebinserschncinun gen. *Arch. Mikr. Anat.*, 20:I. Cited from; pattern and evaluation of alcohols toxicity in patients referred to forensic medicine, poisoning and addiction control center with special emphasis on toxicity in albino rats; Thesis by Hegazy MM, Ass. Lecturer, forensic medicine, and clinical toxicology; Badawy SM, Kamel SM, Mahmoud BL, et al (supervisors); 2005 p 75.
- Flomenbaum NE (2002):** Salicylate, in; Goldfrank's Toxicologic Emergencies; Goldfrank LR, Howland MA, and Flomenbaum NE et al (eds), McGraw-Hill, Medical publishing Division, New York 7th ed. p 507-18.
- Fosslien E (2000):** Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. *Crit Rev Clin Lab Sci*; 37(5):431-52.
- Foster, and Smith (2003):** Etodolac (EtoGesic); Patient information sheet. Po Box 100, Rhinelander, WI 54501 1-800-826-7206
- Francois H, and Coffman TM (2004):** Prostanoids and blood pressure: which way is up? *J Clin Invest*; 114(6): 757-759.
- Furst DE (1997):** Meloxicam: Translating Selective COX-2 Inhibition into Clinical Benefit; *Seminars in Arthritis and Rheumatism*. 26(Suppl1):21-7.
- Gale T, (2006):** Chromosome Structure and Morphology from World of Genetics.chromosome-structure-and-morphology-wog.htm
- Ganem N, Pellman D, and Godinho S (2009):** Link unraveled between chromosomal instability and centrosome defects in cancer cells. *Biology & Nature*; 12:42. © 2009 Eureka! Science News

References

- Gasbarrini G, Griceco A, Mingrone G and et al (2001):** Drug induced liver disease. *Ann Ital Med Int*; 16 (Suppl 4): 1s-80s.
- Gavrieli Y, Sherman Y, and Ben-Sasson SA (1992):** Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *The Journal of cell Biology*; 119(3):493-1.
- Gazarian M, Berkovitch M, Karen G, and et al, (1995):** Experience with misoprostol therapy for NSAID gastropathy in children. *Ann Rheum Dis*. 1995 Apr; 54(4):277-80.
- Genetics Encyclopedia (2003):** Genetics Encyclopedia, Chromosomal Aberrations. [Answers.com chromosomal-aberrations.htm](http://Answers.com/chromosomal-aberrations.htm)
- Girschick HJ, Seyberth HW, and Huppertz HI (1999):** Treatment of childhood hypophosphatasia with nonsteroidal antiinflammatory drugs; *Official Journal of the International Bone and mineral Society*, 25(5):603-7.
- Gisselsson D, (2003):** Chromosome instability in cancer: how, when, and why? *Adv Cancer Res*; 87:1-29.
- Golden BD, and Abramson SB (1999):** Selective COX-2 inhibitors for arthritis: from bench to bedside; *Cutting Edge Repots*; from; <http://www.rheuma21st.com:1-9>.
- Goldsborough (1999):** NSAID Nephropathy and COX-2 Inhibitors nsaid.htm
- Goodin S and Shiff S (2004):** NSAIDs for the chemoprevention of oral cancer: Promise or Pessimism? *Clinical Cancer Research*; 10: 1561-4.
- Gotlieb D (1996):** Meloxicam by drdoc on-line; Meloxicam by drdoc on-line.htm
- Haas DA (2002):** An update on analgesics for the management of acute postoperative dental pain. *J Can Dent Assoc*; 68(8):476-2.
- Hakozaki M, Hoju H, Kikuchi S, and et al (2007):** Etodolac, a selective cyclooxygenase-2 inhibitor, induces apoptosis by activating caspases in

References

- human malignant rhabdoid tumor cells(FR TK-1). *Oncol Rep.* Jan; 17(1):169-7.
- Haldey EJ (2001):** Cardiovascular events and COX-2 inhibitors; Letters, *JAMA*; 286(22): 2808-14.
- Hamilton LC, Mitchell JA, Tomlinson AM and et al, (1999):** Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy. *The FASEB Journal*; 13: 245-1.
- Hamza AA (2007):** Curcuma longa, glycyrrhiza glabra and moringa oleifera ameliorate diclofenac-induced hepatotoxicity in rats. *American Journal of Pharmacology and Toxicology*; 2 (2): 80-8.
- Hartl DL and Jones EW (2001):** Human karyotypes and chromosomes behaviour. In: Genetics analysis of genes and chromosomes. Hartl DL and Jones EW(Eds); Jones and Bartlett Publishers, Inc. Chapter 9 (5th ed); pp. pp. 344-391.
- Hassab El-Nabi SE (2004):** Molecular and cytogenetic studies on the antimutagenic potential of eugenol in human lymphocytes culture treated with depakine and apetryl drugs. *J Egypt Gr Soc Zool*; 43C: 171-96.
- Hawkey CJ (2002):** Cyclooxygenase inhibition: between the devil and deep blue sea; www.gutjnl.com: iii25-iii29.
- Hawkey C, Kahan A, Steinbrück K, and et al (1998):** Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. *Br J Rheumatol*; 37: 937- 4.
- Hoffer L, and Thumb N (1984):** Anti-inflammatorisch wirksame substanzen, ihre wirkung auf DNA synthese und reparatur. In klinische pharmakologie, vol. 4. kuemmerle H (Ed.) Landsberg :Eco-Med Verlag, pp1-12. Adapted from; Ozkul Y, erenmemisoglu A, Ekecik A, and et al (1996): Do Nonsteroidal anti-inflammatory drugs induce sister chromatid

References

- exchange in T lymphocytes? *J Inter Med Res*, 24: 84-87. Cited from Comparative toxicological study between cyclooxygenase-2 inhibitors and some non-steroidal anti-inflammatory drugs in albino rats by El-Kholey SMS; M.b.b.Ch.; Sc., Ahmed MK, Haroun MR, ZAmzam IS, Biomy RZ (Supervisors); 2004 p 281.
- Höglund OV, and Frendin J (2002):** Analgesic effect of meloxicam in canine acute dermatitis: a pilot study. *Acta vet. Scand.*; 43(4): 247-2.
- Höglund OV, Djurklík A, and Frendin J (2003):** Evaluating Analgesic Effect of Carprofen and Meloxicam in Cats after Ovariohysterectomy by Use of Physiologic Parameters. World Small Animal Veterinary Association World Congress Proceedings, MAIN : Oral Presentations: Carprofen and Meloxicam.
- Ho L, Pieroni C, Winger D and et al (1999):** Regional distribution of Cyclooxygenases-2 in the hippocampal formation in Alzheimer's disease. *J Neurosci Res*, 57:295-3.
- Hoshino T, Tsutsumi S, Tomisato W and et al (2003):** Prostaglandin E2 Protects Gastric Mucosal Cells from Apoptosis via EP2 and EP4 Receptor Activation. *J Biol Chem*; 278(15): 12752-58.
- Hosie J, Distel M, and Bluhmki E (1996):** Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium. *Brit J Rheumatol*; 35 (1):39-3.
- Huber T, Ruchti C, and Halter F (1991):** Nonsteroidal antiinflammatory drug-induced colonic strictures: A case report. *Gastroenterology*; 100:1119-22.

References

- Hughes Jr FM, and Cidlowski JA (1994):** Regulation of apoptosis in S49 Cells. *J Steroid Biochem Molec Biol*; 49(4-6):303-10.
- Human (2006):**AS3D Human. List of Medline Publication with reference to gene ATP6V0A2
- Hung RW and Chow AW(2004):** Dissecting the "end game": clinical relevance, molecular mechanisms and laboratory assessment of apoptosis. *Clin Invest Med*; 27(6):324-44.
- Iemoli E, Coen M, Bonfanti P, and et al (2000):** Meloxicam as alternative drug in patients with hypersensitivity to NSAIDs. abstract No.:P-559;file:///A:\All Abstracts for Sydney 2000.htm
- Ingelheim B (2002):** Ellesfield Avenue Bracknell Berkshir RG12 8YS: <http://www.boehringer-ingelheim.co.uk>
- Iowa (2001):** Etodolac; Anti-inflammatory drugs, nonsteroidal (Systemic). The Iowa Clinic Drug Search; Health Library; Scan through our encyclopedia of medical information.
- Jones RL, Watson ML, and Ungar A (1981):** A comparison of the effects of prostaglandins e2 and i2 on renal function and renin release in salt-loaded and salt-depleted anaesthetized dogs. *Quarterly Journal of Experimental Physiology*; 66(1) 1-15.
- Kamijo T, Sato T, Nagatomi Y, and et al (2001):** Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. *International Journal of Urology*; 8(7): S35–S9.
- Kawamori T, Rao CV, Seibert K and et al (1998):** Comprehensive activity of celecoxibe, a specific cyclooxygenases-2 inhibitor, against colon carcinogenesis. *Cancer Res*; 58(3):409-12.

References

- Kern M, Schöneweiß M, Sahi D, and et al (2004):** Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. *Carcinogenesis*; 25(7): 1193-99.
- Kerr JFR, Wyllie AH, and Currie AR (1972):** Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer*; 26:239-57.
- Khandavilli S, and Panchagnula R (2007):** Nanoemulsions as Versatile Formulations for Paclitaxel Delivery: Peroral and Dermal Delivery Studies in Rats. *Journal of Investigative Dermatology*; 127:154-62.
- Kischkel FC, Hellbardt S, Behrmann I, and et al (1995):** Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. *EMBO J*; 14: pp 5579-88.
- Kishimotoa Y, Takata N, Jinnai T, and et al (2000):** Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane. *Gut*; 47: 812-19.
- Kofinas AD (2007):** Kofinas Perinatal Providing Care to the Unborn ® ASPIRIN (ACETYLSALICYLIC ACID). Office Pamphlets\Aspirin_Pregnancy_Lactation
- Kolluri SK, Corr M, James SY and et al (2005):** The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. *Proc Natl Acad Sci*; 102(7): 2525-30.
- Kondo M, Yamamoto H, Nagano H, et al (1999):** Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. *Clinical Cancer Research*; (5): 4005-12.

References

- Koupai-Abyazani MR, Esaw B, and Laviolette B (1999):** Etodolac in equine urine and serum: Determination by high-performance liquid chromatography with ultraviolet detection confirmation, and metabolite identification by atmospheric pressure ionization mass spectrometry; *J of Analyt Toxicol*, (abstract), 23(3): 200-9.
- Kulkarni SK, Jain NK, and Singh A (2000):** Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors; *Methods and Findings in Experimental and Clinical Pharmacology*; 22(5): 291-8.
- Laird JMA, Herrero JF, Rubia PG (1997):** Analgesic activity of the novel COX-2 preferring NSAID, meloxicam in mono-arthritic rats: Central and peripheral components. *Inflammation Research*; 46(6): 203-10.
- Latt SA, Allen J, and Bloom S (1981):** Sister chromatid exchanges; A report of the gene. *Mutat Res*; 87:17-62.
- Lawrence J.(2002):** Non-steroidal anti-inflammatory drugs and antihypertensive drug therapy. *Journal of Hypertension*; 20(5): 849-50.
- Lee SM, O'Brien CJ, Williams R, and et al (1986):** Subacute hepatic necrosis induced by piroxicam. *British Medical Journal*; 293: 540-41.
- Leja D (1999):** Chromosome. National Human Genome Research Institute (NHGRI) <http://www.genome.gov/12514471>
- Lin J, Hsiao PW, Chiu TH, and et al (2005):** Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. *Biochem Pharmacol*; 70(5):658-67.

References

- Liu CH, Chang SH, Narko K, and et al (2001):** Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. *J Biol Chem*; 276(21):18563-69.
- Liu W, Nakamura H, Tsujimura T, and et al (2005):** Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. *Oncol Rep*; 14:409-14.
- Liu X, Kim CN, and Yang J (1996):** Overview of apoptosis. *Cell*; 86:147.
- Loewen PS (2002):** Review of the selective COX-2 inhibitors celecoxib and rofecoxib: focus on clinical aspects. *Pharmacotherapy*; 4(4):1-10.
ploewen@interchange.ubc.ca
- Luberto, C. and Hannun, Y. A. (2004):** Sphingolipids as messengers of cell death. *Journal of Biological Chemistry*; 73: 14550.
- Mabee CL, Mabee SW, and Baker PB et al (1995):** Fulminant hepatic failure associated with etodolac use; *AJG*; 90(4):659-61.
- Majno, G. and Joris, I. (1995):** Apoptosis, oncosis and necrosis: an overview of cell death. *Am. J. Pathol.*; 146:3-15.
- Malernee A (2004):** Evidence Based Vet Forum
Dr. Arthur Malernee's Web Forum - www.ebvet.com
- Manning JS (1994):** Antidepressant augmentation with lithium. *Journal of Family Practice: Case Reports*, 39:379-83.
- Mansfield PR, Vitry AI, and Wright JM (2005):** Withdraw all COX-2-selective drugs. *MJA*; 182(4):197.

References

- Marsden VS and Strasser A (2003):** Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. *Annu Rev Immunol*; 21: 71-105.
- Martin RM, Biswas P, and Mann RD (2000):** The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19087 patients in general practice in England: cohort study. *Blackwell Science Ltd, Br J Clin Pharmacol*; 50: 35-2.
- McClellan P, (1997):** Eukaryotic Chromosome Structure. eukaryo3.htm
- McGettigan p, Platona A and Henry DA (2004):** Renal and cardiovascular toxicity of non-steroidal anti-inflammatory drugs. *Inflammopharmacology*; 8(1):1-18.
- Mendonca LL, Khamashta MA, Neilson-Piercy C, and et al (2000):** Nonsteroidal anti-inflammatory drugs as a possible cause for reversible infertility. *Rheumatology*; 39(8): 880-2.
- Menzies BE, and Kourteva I (1998):** Internalization of Staphylococcus aureus by Endothelial Cells Induces Apoptosis. *Infection and Immunity*; 66(12): 5994-98.
- Merck Veterinary Manual (2006):** Specific Nonsteroidal Anti-inflammatory Drugs. *The Merck Veterinary Manual*; © 2006; Merck & Co., Inc. Whitehouse Station, NJ USA. All Rights Reserved. published in educational partnership with Merial Ltd.
- Mingatto FE, Santos AC, Uyemura S, and et al (1996):** In vitro interaction of nonsteroidal anti-inflammatory drugs on oxidative phosphorylation of rat kidney mitochondria: respiration and ATP synthesis. *Arch Biochem Biophys*; 334(2): 303-8.

References

- Miyajima A, Ito K, Asano T, and et al (2001):** Does cyclooxygenase-2 inhibitor prevent renal tissue damage in unilateral ureteral obstruction? The Journal of Urology; 166: 1124-29.
- Moore BC and Simmons DL (2000):** COX-2 inhibition, apoptosis, and chemoprevention by nonsteroidal anti-inflammatory drugs. dan_simmons@byu.edu 1-15.
- Muscará MN and Wallace JL (1999):** Nitric Oxide V. Therapeutic potential of nitric oxide donors and inhibitors. Am J Physiol Gastrointest Liver Physiol 276 (6): G1313-G1316,
- Nakamura S, Kobayashi M, Shibata K, and et al (2004):** COX-2 independent induction of apoptosis by etodolac in leukemia cells in vitro and growth inhibition of leukemia cells in vivo. Cancer Therapy; 2:153-66.
- Narjes H, Turck D, Busch U, and et al (1996):** Pharmacokinetics and tolerability of meloxicam after i.m. administration. Br J Clin pharmacol; 41:135-9.
- Nidus Info services (2002):** Systemic Lupus Erythematosus. Nidus Information Services, Inc., 41 East 11th Street, 11th Floor, New York, NY 10003 or email office@well-connected.com or on the Internet at ©2002 A.D.A.M., Inc. (or its subsidiaries) www.well-connected.com
- Non-steroidal anti-inflammatory drug (2008):** Wikipedia, the free encyclopedia-Microsoft Internet Explorer
- Nurmikko TJ, Nash TP, and Wiles J R (1998):** Recent advances. British Medical Journal; 317: 1438-41.

References

- Nurtjahja-Tjendraputra E, Ammit AJ, Roufogalis BD, and et al (2003):** Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. *Thrombosis Research*; 111(4-5): 259-65.
- Obe G, Jonas R, Schmidt S (1986):** Metabolism of ethanol in vitro produces a compound which induces sister chromatid exchanges in human peripheral lymphocytes in vitro: acetaldehyde not ethanol is mutagenic. *Mutat Res* (174): 47-1.
- Organisasi BP (2000):** Meloxicam, MONOGRAF UBAT 160. Bahagian Pembangunan Organisasi Dan Teknologi Maklumat Biro Pengawalan Farmacseutikal Kebangsaan Kementerian Kisihatan Malaysia Petaling Jaya; 1-8.
- Ostensen M (1998):** Nonsteroidal anti-inflammatory drugs during pregnancy. *Scand J Rheumatol; Suppl*, 107: 128-32.
- Oxaprozin (2008):** Oxaprozin Revolution Health.
XPPRESP3\Desktop\iron\hn-drug_oxaprozin.htm
- Page J, and Henry D (2000):** Consumption of NSAIDs and the development of congestive heart failure in elderly patients, an underrecognized public health problem. *Arch Intern Med*. 2000; 160: 777-84.
- Parente L (2000):** Pros and Cons of selective inhibition of cyclooxygenase-2 versus Dual Lipoxygenase / cyclooxygenase inhibition: Is two better than one?;Email: lparente@unisa.it
- Parfenova H, Parfenov VN, Shlopov BV, and et al (2001):** Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. *Am J Physiol Cell Physiol*; 281(1): C166-78.
- Piazza GA, Alberts DS, Hixson LJ, and et al. (1997):** Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. *Cancer Res*; 57: 2909-15.

References

- Porter SN, Howarth GS, and Butler RN (2000):** Nonsteroidal anti-inflammatory drugs and apoptosis in the gastrointestinal tract: potential role of the pentose phosphate pathways. *Eur J Pharmacol*; 397(1):1-9.
- Portmann B, Talbot ID, and Day DW (1975):** Histopathological changes in the liver following paracetamol overdose: correlation with clinical and biochemical parameters. *J Pathol*; 117:169-81.
- Prod Data Meloxicam (2001):** BIOMOL Research Laboratories, Inc. www.biomol.com
- Prod Info anti-Inflammatory Drugs (2006):** Anti-inflammatory Drugs. <D:\Documents and Settings\ahmed\serve.htm>
- Prod Info Apotex (2003):** APO®-ETODOLAC Apotex Etodolac Anti-inflammatory The pharmaceutical information APO®-ETODOLAC- Microsoft Internet Explorer
- Prod Info Cyclosporine (2007):** <D:\Documents and Settings\ahmed\d00079a1.htm>
- Prod Info etodolac (1998):** Etodolac Capsules and Tablets; PAR Pharmaceutical, Inc. Spring Valley, New York 10977 USA
- Prod Info etodolac (2002):** www.cilag.chemicals.ch/engDocs/Products/4944.html
- Prod Info etodolac (2003):** Etodolac. www.cilag.chemicals.ch/engDocs/Products/4944.html).
- Prod Info etodolac (2004):** Hitom Chemicals Co. Ltd.; Etodolac www.hitomchem.com
- Prod Info etodolac (2006):** <D:\Documents and Settings\ahmed\healthnotes.htm>
- Prod Info etoGesic (2002):** [file:///A:\EtoGesic Product Information.htm](file:///A:\EtoGesic%20Product%20Information.htm)
<http://www.medi-vet.com/>
- Product Info EtoGesic (2006):** <D:\Documents and Settings\ahmed\15018.htm>

References

- Prod Info Lodine (2003):** Lodine (etodolac) Capsules and Tablets.
D:\Documents and Settings\lodine.htm. Ayerst Laboratories Inc.
- Prod Info meloxicam (2006):** Meloxicam (Systemic); Drug Information
provided by: Micromedex
- Prod Info meloxicam (2007):** Meloxicam (Meloxicam) tablet[Mylan
Pharmaceuticals Inc.] fdaDrugXsl.htm
- Prod Info mobic (2001):** Abcd, Mobic Tablets. Boehringer Ingelheim
International GmbH; 1-13.
- Prod Info mobic (2002):** Summary of the product characteristics.
Boehringer Ingelheim International GmbH Binger Strasse D-55216
Ingelheim; Germany
- Prod Info mobic (2005):** Meloxicam, INDICATIONS AND USAGE;
D:\Documents and Settings\ahmed\Desktop\mobic_ids.htm
- Prod Info Mobicox (2003):** Mobicox - Mobicox Side Effects - Mobicox
Information. D:\New Folder\mobic_warnings.htm Mobicox Meloxicam
- Prod Info NSAIDs (2006):** Nonsteroidal Anti-Inflammatory Drugs.
D:\Documents and Settings\ahmed\nsaids.htm contact@hhsc.state.tx.us
- Prod Info Ultradol (2004):** Ultradol - Ultradol Side Effects - Ultradol
Information Copyright 2004 © RxCC Rx Care Canada. All Rights
Reserved. RxCC Rx Care Canada Inc. 96 Durand Road - Winnipeg,
Manitoba - R2J 3T2 - Canada
- Quaratino D, Romano A, Di Fonso M, and et al (2000):** Tolerability of
meloxicam in patients with histories of adverse reactions to non steroidal
anti-inflammatory drugs. Ann Allergy Asthma Immunol; 84: 613-17.
- Rabinovitz M and Van Thiel DH (1992):** Hepatotoxicity of nonsteroidal
antiinflammatory drugs, Clinical review; The American Journal of
Gastroenterology; 87(12):1696-704.

References

- Rang HP, Dale MM and Ratter JM (2001):** Anti-inflammatory and immunosuppressant drugs; In Pharmacology; Rang HP, Dale MM and Ratter JM (eds) 4th ed; Churchill Livingstone; P229.
- Rbowen, (1996):** Chromosome structure and terminology. rbowen@lamar.colostate.edu
- Reddy MN, Murthy TK, Rajita K, et al (2001):** New spectrophotometric methods for the determination of meloxicam; Indian Journal of Pharmaceutical Sciences; (abstract), 63(3):245-7.
- Reynolds SA, and Burger GT (1994):** Animal care and facilities. In: Principles and methods of toxicology, 3rd ed., Hayes AW (ed.), Raven Press Ltd, New York, P: 497-44.
- Ricchi P, Zarrilli R, and Di Palma A(2003):** Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer; 88(6):803-7.
- Riendeau D, Percival MD, Brindeau C, and et al (2001):** Etoricoxib(MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2; J Pharmacol Exp Ther; 296(2): 558-66.
- Robert J, McKallip, Lombard C, and et al (2002):** Apoptosis in the Thymus and Spleen; Journal of Pharmacology and Experimental Therapeutics; 302(2): 451-55.
- Roberts LJ, and Morrow JD (2001):** Analgesic antipyretic and Anti-inflammatory agents and drugs employed in the treatment of gout; in Goodman and Gilman's, The Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE, and Gilman AG (eds). Library of Congress Cataloging-in-Publication Data; 10th ed, P 695.
- Roberts RA, Soames AR, James NH, and et al, (1995):** Dosing-induced stress causes hepatocyte apoptosis in rat primed by the rodent nongenotoxic hepatocarcinogen cyproterone acetate. Toxicol Appl

References

- Pharmacol; 135(2): 192-8.
- Robinson (1989):** Nsaids anti-inflammatory drugs: How to sort out the choices; Evidence Based Vet Forum Dr. Arthur Malernee's Web Forum - www.ebvet.com
- Rodriguez LA G, Williams R, Derby LE and et al (1994):** Acute liver injury associated with NSAIDs and the role of risk factors. Arch Intern Med; 154(3):311-6.
- Rømsing J, Vilmann P, and Larsen NE (2001):** Postoperative analgesia is not different after local vs. systemic administration of meloxicam in patients undergoing inguinal hernia repair. Canadian Journal of Anesthesia; 48:978-4.
- Rose M, and Walker A (2005):** Renal failure following bowel cleansing with a sodium phosphate purgative. Nephrology Dialysis Transplantation; 20(7):1518-19.
- Roth J, Hübschle T, Pehl U, and et al (2002):** Influence of systemic treatment with cyclooxygenase inhibitors on lipopolysaccharide-induced fever and circulating levels of cytokines and cortisol in guinea-pigs. Pflügers Arch-Eur J Physiol ; 443: 411-17.
- Salvesen GS, and Dixit VM (1999):** Caspase activation; the induced-proximity model. Proc Natl Acad Sci; 96: 10964-7.
- Sanchez G (2004):** ROMI's Website: <http://rimadyideath.Bravenet.com>
- Santos M, Kunkar V, Garcia-Iturralde P, and et al (2004):** Meloxicam, a specific COX-2 inhibitor, does not enhance the isoflurane minimum alveolar concentration reduction produced by morphine in the rat. Anesth Analg; 98: 359-3.

References

- Savage JRK, (1999):** An Introduction to Chromosomal Aberrations. Atlas of Genetics and Cytogenetics in Oncology and Haematology; <http://AtlasGeneticsOncology.org/Deep/Chromaber.html>
- Scarpignato C, Pelosini I.(1999):** Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Ital J Gastroenterol Hepatol; 31(1):S63-72 .
- Schachter AD , Arbus GS, and Alexander RJ(1998):**Non-steroidal anti-inflammatory drug-associated nephrotoxicity in Bartter syndrome; Pediatric Nephrology, 12(9):775-77.
- Schneider V, Lévesque L E, Zhang B, and et al (2006):** Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. American Journal of Epidemiology; 164(9): 881-9.
- Schultz, D.R. and Harrington WJ Jr. (2003):** Apoptosis: programmed cell death at a molecular level. Semin Arthritis Rheum; 32: Pp 345-69.
- Segerer S, Nelson PJ, and Schlöndorff D (2000):** Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol; 11:152-76.
- Sengupta S (1999):** Cyclooxygenase-2: A new therapeutic target; Review Article. Indian Journal of Pharmacology; 31:322-2.
- Setter SM, and Gates BJ (1999):** Osteoarthritis Management in Long-Term Care. Journal of The American Society of Consultant Pharmacists, Inc. 14(5).
- Sharief N, Adams L, butler L and et al (1999):** A child with a DIC (15p; 22p) centric fusion and fetal valproate syndrome. Case Report: Indian Pediatrics; 36: 507-10.
- Sheng H, Shao J, Morrow JD, and et al (1998):** Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.

- Cancer Res; 58(2): 362-6.
- Shi Y (2004):** Caspase activation; revisiting the induced proximity model. Cell; 117: 855-8.
- Simmons DL, Botting RM, and Hla T (2004):** Cyclooxygenase isozymes: The biology of prostaglandin synthesis and inhibition. Pharmacol Rev; 56:387-37.
- Simon LS (2000):** Specific COX-2 therapy is the future. JCOM; 7(1): 56-7.
- Singh NP (2000):** Rapid communication; A simple method for accurate estimation of apoptotic cells; Experimental cell research; 256: 328-7.
- Singh NP, and Khan A (1995):** Acetaldehyde: genotoxicity and cytotoxicity in human lymphocytes. Mutat Res (337): 9-17.
- Skinner T (2003):** Nursing & Healthcare directories on: the nursefriendly nonsteroidal anti-inflammatories, NSAIDS, pain killers Lodine, etodolac. <http://www.lopez1.com/lopez/drugs/nonsteroidal.anti.inflammatories/lodine.etodolac.htm>: 1-5.
- Slagle MA (2001):** Featured CME topic: pain management, medication update. Southern Medical Journal; 94(8): 771-4.
- Slee EA, Adrain C, and Martin SJ (1999):** Ordering caspase activation events in apoptosis. Cell Death Differ; 6:1067-74.
- Staerckel P, and Horsmans Y (1999):** Meloxicam-induced liver toxicity. Acta Gastroenterology Belg; 62(2):255-6.
- Stokes JB, and Kokko JP (1977):** Inhibition of sodium transport by prostaglandin E2 across the isolated, perfused rabbit collecting tubules. J Clin Invest; 59(6): 1099-104.
- Stöhlberger C, and Finsterer J (2004):** Both Thrombotic and Nonthrombotic Cardiovascular and Cerebrovascular Side Effects of Nonsteroidal Anti-Inflammatory Drugs Should Be Considered Stroke.;35:e26 Letters to the Editor

References

- Sükrü Z, Kseoglu, BG, Hülya K, and et al (2004):** In vitro effects of selective and non-selective nonsteroidal anti-Inflammatory drugs on the frequency of sister chromatid exchanges. *Drugs in R & D*; 5(6): 327-30.
- Sun T, Li S, Diao HL, and et al (2004):** Cyclooxygenases and prostaglandin E synthases in the endometrium of the rhesus monkey during the menstrual cycle. Copyright © 2004 Society for Reproduction and Fertility
zmyang@mail.neau.edu.cn
- Supernaw RB (2002):** Pain management: Important principles in the drug management of pain. *Hospital Physician* ; 45-2. www.turner-white.com
- Tachibana M, Inoue N, Yoshida E, and et al (2003):** Anti-Inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats. *Pharmacology*; 68(2):96-4.
- Takano T, Cybulsky AV, Cupples WA, and et al (2003):** Inhibition of Cyclooxygenases Reduces Complement-Induced Glomerular Epithelial Cell Injury and Proteinuria in Passive Heymann Nephritis. *Journal of Pharmacology and Experimental Therapeutics*; 305(1): 240-49.
- Tegeder I, Neupert W, Gühring H, and et al (2000):** Effect of selective and unselective cyclooxygenase inhibitors on prostanoid release from various rat organs. *The Journal of Pharmacology and Experimental therapeutics*; 292:1161-8.
- Thome M, Schneider P, Hofmann K, and et al (1997):** Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. *Nature*; 386: 517-21.
- Thome M and Tschopp J (2001):** Regulation of lymphocyte proliferation and death by FLIP. *Nat Rev Immunol*; 1:50-8.
- Thompson, J.S. and Thompson, M.W. (1980):** *Genetics in Medicine*, 1st Edn., Saunders, W.B. Company, Philadelphia, London, Toronto, Mexico City. Rio de Janeiro, Sydney, Tokyo .pp: 125-126.

References

- Thorburn A (2004):** Death receptor-induced cell killing. *Cell Signal*; 16:139-44.
- Thornberry NA and Lazebnik Y Caspases (1998):** Enemies within. *Science*; 281:1312-6.
- Tolman KG (1998):** Hepatotoxicity of non-narcotic analgesics. *Am J Med*; 105(1B):13s-19s.
- Trexall (2008):** Trexall side effects (mesotrexate) and drug interactions-prescription drug and medication. Copyright © 2008 by RxList Inc. XPPRESP3\Desktop\mtx_ad.htm
- Tsuneoka N, Tajima Y, Kitazato A, and et al (2005):** Chemopreventative effect of a cyclooxygenase-2-specific inhibitor (etodolac) on chemically induced biliary carcinogenesis in hamsters. *Carcinogenesis*; 26(2):465-9.
- Turek D, Schwarz A, Hoffler D, and et al (1996):** Pharmacokinetics of meloxicam in patients with end-stage renal failure on haemodialysis: a comparison with healthy volunteers. *Eur J Clin Pharmacol*; 1996; 51 (3-4):309-13.
- Van Kraaij DJW, Vollaard EJ, De Metz M, and et al (2000):** A comparison of the effects of nambutone vs meloxicam on serum thromboxane B² and platelet function. *Br J Clin Pharmacol*; 51:499-500.
- Vane JR, BakhleYS, and Botting RM (1998):** Cyclooxygenase 1 and 2. *Annu Rev Pharmacol Toxicol*; 38: 97-20.
- Vane SJ (2000):** Aspirin and other anti-inflammatory drugs; *Thorax*; 55(Suppl 2):S3-S9.
- Vaux DL, Cory S and Adams JM (1988):** Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature*; 335:440-2.
- Villegas I, Lastra CA, Martín MJ, and er al (2002):** Gastric damage induced by subchronic administration of preferential cyclooxygenase-1 and cyclooxygenase-2 inhibitors in rats. *Pharmacology*; 66:68-5.

References

- Walker AM (1997):** Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal anti-inflammatory drugs. *Arthritis Rheum*; 40(2):201-8.
- Wallace JL, Bak A, McKnight W, and et al (1998):** Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. *Gastroenterology*; 115(1):101-9.
- Walsh JH (2001):** NSAIDS of the 21st century and their GI effects. file://A:\melox---E.htm : 1-7.
- Wang JL, Cheng HF, Shappell S, and et al (2000):** A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. *Kidney international*; 57: 2334-42.
- Wang LD, Zhou Q, Wei JP, and et al (1998):** Apoptosis and its relationship with cell proliferation, P53, Waf1P21, bcl-2 and c-myc. In: oesophageal carcinogenesis studied with a high-risk population in northern china. *World J. Gastroenterol.*; 4:287-93.
- Wang M, Honn KV, and Nie D (2007):** Cyclooxygenases, prostanoids, and tumor progression. *Cancer and Metastasis Reviews*; 26(3-4):525-34.
- Watson WA (2002):** Nonsteroidal anti-inflammatory agent, in: Goldfrank's Toxicologic Emergencies; Goldfrank LR, Howland MA, and Flomenbaum NE et al (eds), McGraw-Hill, Medical publishing Division, New York 7th ed. P 528.
- Webster J (1985):** Interactions of NSAIDs with diuretics and beta-blockers; mechanisms and clinical implications. *Drugs*; 30(1):32-41.
- Whelton A (2001):** Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. *Am J Med*; 110: 33s-2s.
- Wikipedia(2006):**Chromosome abnormality.
"http://en.wikipedia.org/wiki/Chromosome_abnormality
- Wikipedia (2008):** Non-steroidal anti-inflammatory drug
"http://en.wikipedia.org/wiki/Non-steroidal_anti-inflammatory_drug"

References

- Wolfe MM, Lichtenstein DR, and Singh AG (1999):** Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs; Review Article. The New England Journal of Medicine; 340(24): 1888-98.
- Wood J (1999):** Musculoskeletal disorders (3) Rheumatoid arthritis: the disease and its management with NSAIDs. The Pharmaceutical Journal 262 (7050): 881-4.
- Wright JM (2002):** The double-edged sword of COX-2 selective NSAIDs. Canadian Medical Association J; 167(10): 1131-7. www.healthnotes.com
- Yasui H, Hideshima T, Hamasaki M, and et al (2005):** SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood; 106(2): 706-12.
- Yeomans ND, Cook GA, and Giraud AS (1998):** Selective COX-2 inhibitors: are they safe for the stomach? Editorials; Gastroenterology; 115(1):227-9.
- Zimmerman BT, Crawford GD, and Dahl R (1995):** Mechanism of acetaldehyde mediated growth inhibition: delayed cell cycle progression and induction of apoptosis. Alcohol Clin Exp Res (19): 434-40.